Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.

Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.

Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.

Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.

Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.

Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.